Momelotinib

(Ojjaara®)

Ojjaara®

Drug updated on 9/4/2024

Dosage FormTablet (oral; 100 mg, 150 mg, 200 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Ojjaara (momelotinib) is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • Momelotinib, ruxolitinib, and fedratinib demonstrated comparable efficacy in reducing spleen volume and total symptom scores in patients with myelofibrosis when used as first-line treatments.
  • Pacritinib was less effective than ruxolitinib in treating splenomegaly in first-line therapy but appeared effective in second-line treatment after prior ruxolitinib exposure.
  • The studies did not explicitly mention differences in effectiveness across specific populations or subgroups.
  • Momelotinib demonstrated less toxicity related to erythrocytes and platelets compared to ruxolitinib and fedratinib, with a positive effect on anemia and reduced thrombopenia risk.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Ojjaara (momelotinib) Prescribing Information.2023GlaxoSmithKline LLC., Philadelphia, PA

Systematic Reviews / Meta-Analyses